[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-non-small-cell-lung-cancer-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-non-small-cell-lung-cancer-nsclc":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645238","phase-2-a-study-to-assess-the-safety-tolerability-and-efficacy-of-imzokitug-in-combination-with-pumitamig-and-platinum-doublet-chemotherapy-pdct-versus-pumitamig-and-pdct-as-first-line-treatment-for-participants-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc-100645238",false,"NCT07680764","A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria\n\n* Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.\n* Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.\n* Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site.\n* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n\nExclusion Criteria\n\n* Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.\n* Participants must not have prior treatment with immuno-oncology therapies.\n* Participants must not have untreated central nervous system (CNS) metastases.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[26,27],"Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","Metastatic Non-Small Cell Lung Cancer (NSCLC)",[29,30,31,32,33,34],"Squamous Non-Small Cell Lung Cancer (NSCLC)","Non-squamous Non-Small Cell Lung Cancer (NSCLC)","Immunotherapy","Bispecific antibody","Imzokitug","Anti-CCR8 monoclonal antibody","NOT_YET_RECRUITING","2026-06-26",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":20},"2026-08-15",{"date":43,"type":20},"2030-09-15",{"name":45,"class":46},"Bristol-Myers Squibb","INDUSTRY",71,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100644622","phase-2-phase-ii-trial-of-sfrt-plus-chemo-immunotherapy-for-la-nsclc-with-suboptimal-neoadjuvant-response-100644622","NCT07670715","Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response","Spatially Fractionated Radiotherapy Combined With Chemo-immunotherapy for Locally Advanced Non-Small Cell Lung Cancer With Suboptimal Response to Initial Neoadjuvant Therapy: A Single-Arm, Open-Label, Phase II Study","Inclusion Criteria:\n\n1. Histologically confirmed unresectable stage III locally advanced non-small cell lung cancer (LA-NSCLC).\n2. Received at least 2 cycles of standard neoadjuvant chemoimmunotherapy, with suboptimal tumor response verified by post-induction radiological evaluation.\n3. Age ≥ 18 years old.\n4. ECOG performance status of 0 or 1.\n5. Adequate hematologic, hepatic and renal function to complete radiotherapy and consolidation systemic therapy.\n6. Voluntarily sign written informed consent and be capable of following study-related procedures.\n\nExclusion Criteria:\n\n1. Prior thoracic radiotherapy history.\n2. Active uncontrolled autoimmune disorders or persistent severe immune-related adverse events.\n3. Untreated symptomatic brain metastases.\n4. Severe irreversible cardiac, pulmonary, liver or renal dysfunction that cannot tolerate combined radiotherapy and immunotherapy.\n5. Pregnant or breastfeeding women.\n6. Concurrent or previous other malignant tumors within 5 years, except cured basal cell skin cancer and cervical carcinoma in situ.\n7. Any absolute contraindication to lattice radiation therapy or immune checkpoint inhibitor.",{"count":56,"type":20},30,[23],"Lattice radiation therapy (LRT) is a spatially fractionated thoracic radiotherapy technique that creates alternating high- and low-dose regions within primary lung tumors and metastatic lymph nodes to strengthen local tumor suppression and reduce radiation injury to normal thoracic organs. This study aims to evaluate the efficacy and safety of combining LRT with consolidation chemoimmunotherapy in unresectable stage III LA-NSCLC patients who show suboptimal tumor response to prior neoadjuvant chemoimmunotherapy, through a single-arm Phase II clinical trial. Patients will receive thoracic LRT delivered by a medical linear accelerator. High-dose spherical sub-targets will be contoured within the gross tumor volume of primary lung lesions and regional nodal metastases under standardized dose constraints to spare the lung, heart and esophagus. All enrolled subjects will receive sequential consolidation chemoimmunotherapy administered within one week after finishing LRT. Tumor response, treatment-related adverse events, local tumor control and long-term survival outcomes will be prospectively tracked throughout treatment and long-term follow-up.",[60,61,62,63],"Locally Advanced Non-small Cell Lung Cancer (NSCLC)","Thoracic Radiotherapy","Immune Checkpoint Inhibitors","Neoadjuvant Chemoimmunotherapy",[65,66,63],"spatially fractionated radiotherapy","Locally Advanced NSCLC","2026-06-22",{"date":36,"type":39},{"date":70,"type":20},"2026-07-01",{"date":72,"type":20},"2028-07-01",{"name":74,"class":75},"Tianjin Medical University Cancer Institute and Hospital","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":5},"100629802","effect-of-pre-operative-exercise-training-on-cardiorespiratory-fitness-in-patients-with-locally-advanced-non-small-cell-lung-cancer-undergoing-induction-chemo-immunotherapy-followed-by-surgery---a-randomized-controlled-study-100629802","NCT07479407","Effect of Pre-operative Exercise Training on Cardiorespiratory Fitness in Patients With Locally Advanced Non-small Cell Lung Cancer Undergoing Induction Chemo-immunotherapy Followed by Surgery - a Randomized Controlled Study","PREHAB","Inclusion Criteria:\n\n* Age ≥18 years.\n* Confirmed diagnosis of stage IIB, IIIA, IIIB or oligo-metastatic stage IV NSCLC.\n* Planned induction therapy with either chemotherapy, immunotherapy or a combination of immuno-chemotherapy followed by an anatomical pulmonary resection.\n* Absence of musculoskeletal conditions preventing safe physical exercise.\n* Absence of any history of uncontrolled or unstable cardiac disease.\n* Agreement to participate in the study by signing the study specific informed consent form.\n\nExclusion Criteria:\n\n* Pregnancy (confirmed by a test if applicable).\n* Induction therapy already initiated.\n* Inability to walk independently.\n* Lack of decision-making capacity.\n* Oxygen-dependency before the initiation of the induction protocol.\n* No capacity for discernment.\n* Does not speak French.",{"count":85,"type":20},74,[87],"NA","The PREHAB study focuses on patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant chemotherapy and\u002For immunotherapy prior to surgical resection. These systemic treatments frequently impair patients' physiological reserve, reduce physical fitness, and may occasionally lead to cancellation of surgery. Surgery itself carries a substantial risk of cardiorespiratory complications and long-term functional decline.\n\nThe primary objective of this study is to determine whether a supervised exercise program, initiated concomitantly with systemic therapy and continued until surgery, can improve cardiorespiratory fitness, surgical tolerance, and postoperative outcomes.\n\nA total of 74 patients will be randomly assigned to one of two groups: an \"intervention\" group participating in three weekly sessions of supervised endurance and resistance training for 12 to 16 weeks under the guidance of a physiotherapist, and a \"control\" group receiving usual care without a structured exercise program.\n\nThe primary endpoint will be peak oxygen uptake (VO₂peak). Secondary outcomes will include postoperative complication rates, length of hospital stay, pulmonary function, skeletal muscle mass, and quality of life.\n\nIntervention-related risks, primarily falls or overexertion, will be mitigated through professional supervision. This multicenter study, with recruitment scheduled to begin in 2026, is expected to provide robust evidence regarding the effectiveness of targeted exercise training in improving preoperative fitness and postoperative recovery in patients with locally advanced NSCLC.",[60],[91,92,93,31,94,95,96,97,98,99],"Non-small cell lung cancer","Locally advanced NSCLC","Neoadjuvant therapy","Prehabilitation","Exercise training","VO2peak","Cardiopulmonary exercise testing","Thoracic surgery","Postoperative complications","2026-03-16",{"date":102,"type":39},"2026-03-18",{"date":104,"type":20},"2026-04",{"date":106,"type":20},"2029-04",{"name":108,"class":75},"Hôpital du Valais","Locally Advanced Non Small Cell Lung Cancer (NSCLC)"]